News

An Interview with Michael D. Iseman, M.D.

Professor of Medicine, University of Colorado School of Medicine, Denver, Colorado

This video was recorded on November 13, 2009 at Johns Hopkins University.

MIchael D. Iseman
Michael D. Iseman

Dr. Michael D. Iseman is a Professor of Medicine in the Divisions of Pulmonary Medicine and Infectious Diseases at the University of Colorado School of Medicine.

Dr. Iseman grew up in Fremont, Nebraska. He received an A.B. with honors in history from Princeton University in 1961 and an M.D. from Columbia College of Physicians and Surgeons in 1965.

After his internship and junior residency in medicine at the Columbia service at Bellevue Hospital (1965-1967), he served as a medical officer in the U.S. Navy (1967-1969). He returned to New York City to complete his medicine residency and fellowship in pulmonary medicine on the Columbia Service at Harlem Hospital (1969-1972).

In 1972 he joined the faculty of the University of Colorado School of Medicine. For 10 years he was on the staff of Denver General Hospital, including directorship of the Metropolitan TB Clinic.

In 1982, Dr. Iseman joined the faculty of the National Jewish Medical and Research Center, acting as Director of the Mycobacterial Disease Service from 1982-2004. He served as an Associate Editor (for TB) for the American Journal of Respiratory and Critical Care Medicine from 1984 to 1989 and was Editor-in-Chief of The International Journal of Tuberculosis and Lung Disease (Paris) from 1997-2002.

In addition to numerous articles and editorials, Dr. Iseman single-authored a textbook, “A Clinician’s Guide to Tuberculosis” (Lippincott, 2000). He has lectured in 47 states and 36 foreign countries and has served as a consultant to the U.S. Centers for Disease Control and the World Health Organization for TB. Dr. Iseman has been Director of “The Denver TB Course” from 1983 to the present, hosting over 3,000 physicians, nurses and public health workers in this period.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...